NATCO Pharma informs about disclosure

23 Apr 2024 Evaluate
Further to its earlier intimation dated November 2, 2023 about the successful completion of United States Food and Drug Administration’s (USFDA) inspection of the firm’s compliance to Pharmacovigilance requirements with zero observations, NATCO Pharma has informed that the Company is in receipt of the Establishment Inspection Report (EIR) from USFDA concluding the inspection as Closed.

The above information is a part of company’s filings submitted to BSE.

Natco Pharma Share Price

797.60 -38.80 (-4.64%)
04-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1709.40
Dr. Reddys Lab 1109.75
Cipla 1415.55
Lupin 1971.10
Zydus Lifesciences 866.65
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...